Comparison of Continuous and Pulsatile Apomorphine in Parkinson's Disease - NCT00758368-97239 (Clinical Trial 243073)
Permalink: http://www.ClinicalConnection.com/exp/ExpandedPatientViewStudy243073.aspx
|
** Please review additional "Nearby Studies" on right ----->
|
|
 |
 |
|
| City: |
|
Portland |
|
State:
|
|
OR |
| Zip Code: |
|
97239 |
| Conditions: |
|
Parkinson's Disease |
| Purpose: |
|
The purpose of this study is to compare the effects of apomorphine, given by two different
methods, to determine how best to manage dyskinesias.
|
| Study summary: |
|
Levodopa is a drug that can be taken by mouth, and improves the symptoms of Parkinson's
disease (PD). However it can eventually cause involuntary movements called dyskinesia and
motor fluctuations—fluctuations in the control of symptoms, often referred to as "off" and
"on." Apomorphine is a drug that works as well as levodopa, but does not work if taken by
mouth.
The purpose of this study is to compare the effects of apomorphine in people with PD who
have levodopa-induced motor fluctuations and dyskinesias. In the trial, researchers will
compare the effects of apomorphine administered by subcutaneous bolus injections (pulsatile)
and by ambulatory infusion pumps (continuous) in 24 people with PD, for 6 months.
After an initial screening, potential participants will undergo a test to verify that they
can tolerate and respond to apomorphine. Those who meet all of the requirements will be
randomized to receive the study drug via injections (shots) using an injector pen or a
portable infusion pump. Apomorphine will be given either continuously using the portable
pump during the waking day or intermittently by injection, for 6 months. The pump will be
carried on a belt and connected by a tube to a small needle under the skin. Injections of
apomorphine under the skin will be self-administered by the participants or administered by
friends or family members using injector pens.
After 6 months, the effects of apomorphine use will be assessed by measuring how the
participants respond to levodopa and by measuring their symptoms during the course of the
study. Participants will be followed initially every week, then biweekly, and then monthly
in an outpatient clinic for 6 months. During this time, they may receive adjustments of
apomorphine doses as well as doses of other antiparkinson medications. |
| Criteria: |
|
Inclusion Criteria:
- idiopathic Parkinson's Disease
- clear response to levodopa (sinemet)
- "off" at least 20% of waking day
- dyskinesias present for at least two hours of waking day
- subject or caregiver able to master use of drug delivery system (injector pen or
pump)
Exclusion Criteria:
- physical complications that would preclude safe participation
- standing systolic BP of <80
- lack of tolerance or response to apomorphine
- drug/alcohol abuse |
|
|
|
| Study is available at: |
|
Oregon Health and Science University
Portland, OR 97239
United States
Primary Contact:
Erica Myruski, BSN, MPH
Email: myruski@ohsu.edu
Phone: 503-494-9531
Secondary Contact:
Erica Myruski, BSN, MPH
Email: myruski@ohsu.edu
Phone: 503-494-9531 |
|
|
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
|
| Trials Alerts: |
|
If you would like to be
notified of new clinical trials as they become available please
register for a free account.
|
|
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
March 16, 2010 |
Modifications to
this listing: |
|
Only selected fields are shown, please use the link
above to view all information about this clinical trial. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Clinical trials are medical research studies designed to test the safety and/or
effectiveness of new drugs, devices, or treatments in humans. These studies are
conducted worldwide for a range of conditions and illnesses. Learn more about
clinical research and participating in a study at
About Clinical Trials.
|
|
|
|
|